SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Buono Linda (Last) (First) (Middle) C/O AEGERION PHARMACEUTICALS, INC. ONE MAIN STREET, SUITE 800 (Street) CAMBRIDGE MA 02142 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 08/30/2016	3. Issuer Name and Ticker or Trading Symbol Aegerion Pharmaceuticals, Inc. [ AEGR ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Sr. VP, Human Resources	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	03/14/2026	Common Stock	75,000	$5.43(2)	D
Stock Option (right to buy)	(3)	05/09/2026	Common Stock	7,000	$2.46(2)	D
Restricted Stock Units	(4)	(4)	Common Stock	4,000	(5)	D

Explanation of Responses:

1. 25% of the shares of common stock underlying this stock option award will vest on March 14, 2017, with the remaining 75% of the shares of common stock underlying this stock option award vesting thereafter in equal monthly installments through March 14, 2020, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.

2. The stock option award has an exercise price equal to the closing price of the Issuer's common stock on the NASDAQ Global Select Market on the date of grant.

3. 25% of the shares of common stock underlying this stock option award will vest on May 9, 2017, with the remaining 75% of the shares of common stock underlying this stock option award vesting thereafter in equal monthly installments through May 9, 2020, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer.

4. Subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer, the restricted stock units will vest and become exercisable as to 33.34% of the units on May 9, 2017; 33.33% of the units on May 9, 2018; and 33.33% of the units on May 9, 2019.

5. Each restricted stock unit represents a contingent right to receive one share of common stock.

	/s/ Jennifer Fitzpatrick, attorney-in-fact	09/08/2016
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.